Unfractionated heparin inhibits live wild type SARS‐CoV‐2 cell infectivity at therapeutically relevant concentrations

Background and Purpose Currently, there are no licensed vaccines and limited antivirals for the treatment of COVID‐19. Heparin (delivered systemically) is currently used to treat anticoagulant anomalies in COVID‐19 patients. Additionally, in the United Kingdom, Brazil and Australia, nebulised unfrac...

Celý popis

Uloženo v:

Podrobná bibliografie
Vydáno v:	British journal of pharmacology Ročník 178; číslo 3; s. 626 - 635
Hlavní autoři:	Tree, Julia A., Turnbull, Jeremy E., Buttigieg, Karen R., Elmore, Michael J., Coombes, Naomi, Hogwood, John, Mycroft‐West, Courtney J., Lima, Marcelo A., Skidmore, Mark A., Karlsson, Richard, Chen, Yen‐Hsi, Yang, Zhang, Spalluto, Cosma Mirella, Staples, Karl J., Yates, Edwin A., Gray, Elaine, Singh, Dave, Wilkinson, Tom, Page, Clive P., Carroll, Miles W.
Médium:	Journal Article
Jazyk:	angličtina
Vydáno:	England Blackwell Publishing Ltd 01.02.2021 John Wiley and Sons Inc
Témata:	ACE2 Angiotensin-converting enzyme 2 Angiotensin-Converting Enzyme 2 - metabolism Animals Anticoagulants Antiviral activity Antiviral agents Antiviral Agents - pharmacology Antiviral drugs Chlorocebus aethiops COVID-19 COVID-19 Drug Treatment Heparin Heparin - metabolism Heparin - pharmacology Heparin - therapeutic use Heparin, Low-Molecular-Weight - pharmacology Infectivity LMWH nebulised Patients Protein Binding - drug effects Proteins Research Paper Research Papers SARS-CoV-2 - growth & development SARS‐CoV‐2 Severe acute respiratory syndrome coronavirus 2 Spike Glycoprotein, Coronavirus - metabolism Spike protein Therapeutic applications UFH Viral Plaque Assay Australia COVID-19 heparin nebulised LMWH SARS-CoV-2 UFH
ISSN:	0007-1188, 1476-5381, 1476-5381
On-line přístup:	Získat plný text
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!

Buďte první, kdo okomentuje tento záznam!